JN.1 sub-variant: The Additional Public Health Risk Is Low at the Global Level

JN.1 sub-variant whose earliest documented sample was reported on 25 August 2023 and which was later reported by the researchers to have higher transmissibility and immune escape ability, has now been designated a variant of interest (VOIs) by WHO.

In the last few weeks, JN.1 cases have been reported in many countries. Its prevalence is rapidly increasing globally. In view of rapidly increasing spread, WHO has classified JN.1 as a separate variant of interest (VOI).

As per initial risk evaluation by WHO, the additional public health risk posed by JN.1 sub-variant is low at the global level.

Notwithstanding higher infection rate and possibility of immunity evasion, current evidence does not suggest that the disease severity could be higher compared to other circulating variants.

***

References:

  1. WHO.  Tracking SARS-CoV-2 variants – Currently circulating variants of interest (VOIs) (as of 18 December 2023). Available at https://www.who.int/activities/tracking-SARS-CoV-2-variants
  2. WHO. JN.1 Initial Risk Evaluation 18 December 2023. Available at https://www.who.int/docs/default-source/coronaviruse/18122023_jn.1_ire_clean.pdf?sfvrsn=6103754a_3 

***

Latest

Brain-Computer Interfaces (BCI): Towards Humans’ Merger with AI 

The ongoing clinical trials of Brain-Computer Interfaces (BCIs) such...

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both...

Future Circular Collider (FCC): CERN Council reviews Feasibility Study

The quest for the answers to the open questions (such as, which...

Chernobyl Fungi as Shield Against Cosmic Rays for Deep-Space Missions 

In 1986, the 4th unit of Chernobyl Nuclear Power Plant in Ukraine...

Myopia Control in Children: Essilor Stellest Eyeglass Lenses Authorised  

Myopia (or near-sightedness) in children is a highly prevalent...

Newsletter

Don't miss

Growing Neanderthal Brain in the Laboratory

Studying the Neanderthal brain can reveal genetic modifications which...

Weight-Based Dosing of Aspirin for Prevention of Cardiovascular Events

Study shows that a person’s body weight influences the...

Moderate Alcohol Consumption May Decrease Risk of Dementia

A study suggests that both excessive consumption of alcohol...

Bionic Eye: Promise of Vision for Patients With Retinal and Optic Nerve Damage

Studies has shown that the “bionic eye” promises to...

XPoSat : ISRO launches World’s Second ‘X-ray Polarimetry Space Observatory’  

ISRO has successfully launched the satellite XPoSat which is...

COVID-19: Use of Hyperbaric Oxygen Therapy (HBOT) in Treatment of Severe Cases

COVID-19 pandemic has caused a major economic impact all...
SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Brain-Computer Interfaces (BCI): Towards Humans’ Merger with AI 

The ongoing clinical trials of Brain-Computer Interfaces (BCIs) such as Neuralink’s “Telepathy” implant involve establishing communication links between the brains of participants who have unmet medical needs due...

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced by electric fields. Application of alternating electric fields (TTFields) to solid tumours selectively target and...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both strategic investment and active contribution in shaping its future direction.  Scientific European is an England-based media outlet providing multilingual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.